Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis

医学 2型糖尿病 内科学 胰岛素 胰高血糖素样肽1受体 糖尿病 低血糖 内分泌学 减肥 兴奋剂 基础(医学) 体重增加 荟萃分析 肥胖 受体 体重
作者
Conrad Eng,Caroline Kaercher Kramer,Bernard Zinman,Ravi R. Retnakaran
出处
期刊:The Lancet [Elsevier BV]
卷期号:384 (9961): 2228-2234 被引量:388
标识
DOI:10.1016/s0140-6736(14)61335-0
摘要

Combination treatment with a glucagon-like peptide-1 (GLP-1) agonist and basal insulin has been proposed as a treatment strategy for type 2 diabetes that could provide robust glucose-lowering capability with low risk of hypoglycaemia or weight gain. We thus did a systematic review and meta-analysis of randomised controlled trials to assess the effect of this combination treatment on glycaemic control, hypoglycaemia, and weight gain in patients with type 2 diabetes.We systematically searched PubMed, Embase, Cochrane, Web of Knowledge, FDA.gov, and ClinicalTrials.gov for randomised controlled trials (published between Jan 1, 1950, and July 29, 2014; no language restrictions) comparing GLP-1 agonist and basal insulin combination treatment to other anti-diabetic treatments. Our main endpoints were glycaemic control, hypoglycaemia, and change in weight. We assessed pooled data by use of a random-effects model.Of 2905 identified studies, 15 were eligible and were included in our analysis (N=4348 participants). Compared with other anti-diabetic treatments, GLP-1 agonist and basal insulin combination treatment yielded an improved mean reduction in glycated haemoglobin (HbA1c) of -0·44% (95% CI -0·60 to -0·29), an improved likelihood of achieving the target HbA1c of 7·0% or lower (relative risk [RR] 1·92; 95% CI 1·43 to 2·56), no increased relative risk of hypoglycaemia (0·99; 0·76 to 1·29), and a mean reduction in weight of -3·22 kg (-4·90 to -1·54). Furthermore, compared with basal-bolus insulin regimens, the combination treatment yielded a mean reduction in HbA1c of -0·1% (-0·17 to -0·02), with lower relative risk of hypoglycaemia (0·67, 0·56 to 0·80), and reduction in mean weight (-5·66 kg; -9·8 to -1·51).GLP-1 agonist and basal insulin combination treatment can enable achievement of the ideal trifecta in diabetic treatment: robust glycaemic control with no increased hypoglycaemia or weight gain. This combination is thus a potential therapeutic strategy that could improve the management of patients with type 2 diabetes.None.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
正直凡灵发布了新的文献求助10
刚刚
Einsteinwyuh发布了新的文献求助10
刚刚
资浩阑完成签到,获得积分10
刚刚
1秒前
emily发布了新的文献求助10
1秒前
1秒前
sun完成签到 ,获得积分10
1秒前
midx发布了新的文献求助10
1秒前
Na发布了新的文献求助10
2秒前
zhaoyuan完成签到,获得积分10
2秒前
听话的可乐完成签到,获得积分10
3秒前
勤劳的冰淇淋完成签到 ,获得积分10
3秒前
Jeff_Lin完成签到,获得积分10
3秒前
3秒前
领导范儿的应助被程浩磊采纳,获得10
3秒前
xhgxfh发布了新的文献求助10
4秒前
4秒前
4秒前
周青春偶像完成签到,获得积分10
4秒前
ZHOUZHOU完成签到,获得积分10
4秒前
研友_VZG7GZ的应助被单纯的乐曲采纳,获得10
5秒前
核桃发布了新的文献求助10
5秒前
pan发布了新的文献求助10
5秒前
6秒前
6秒前
6秒前
moooo发布了新的文献求助10
8秒前
bbh56发布了新的文献求助10
8秒前
8秒前
好家伙发布了新的文献求助10
9秒前
忧郁蓝调发布了新的文献求助10
10秒前
molihuakai的应助被求知采纳,获得10
10秒前
11秒前
於笑槐完成签到,获得积分10
12秒前
12秒前
Jeff_Lin发布了新的文献求助10
13秒前
maguodrgon发布了新的文献求助10
13秒前
nannan完成签到,获得积分20
14秒前
icymars完成签到,获得积分10
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
Monte Cassino in the Middle Ages Volume I 310
JUSTIFICATION OF SMALL-SCALE MODELS: AN INDUSTRY PERSPECTIVE 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8156628
求助须知:如何正确求助?哪些是违规求助? 9552750
关于积分的说明 21711279
捐赠科研通 7745718
什么是DOI,文献DOI怎么找? 3426593
关于科研通互助平台的介绍 2551401
邀请新用户注册赠送积分活动 2470435